International
Available Domestic
International
Available Domestic
Dragon Pharma
Dragon Pharma CJC-1295 DAC 5 mg Long-Acting GHRH Research Vial
Injection · 5 mg/ml · vial
In stock · ships within 24h
Out of stock
$115.00
Dragon Pharma CJC-1295 DAC is a 5 mg lyophilized vial of a GHRH analogue fitted with the DAC albumin anchor, the modification that turns a short pulse into a rise lasting days. It is supplied as research material rather than a medicine.
GMP-manufactured, HPLC-verified with the Certificate of Analysis on file. CJC-1295 DAC for sale with U.S. domestic and international shipping.
Shipping
Not available in this combination
Discreet plain packaging
Worldwide reship guarantee
Crypto & card accepted
Product overview
Dragon Pharma CJC-1295 DAC 5 mg GHRH Analogue Vial
CJC-1295 DAC is a modified growth hormone releasing hormone analogue with four amino acid substitutions that resist enzymatic breakdown, plus a drug affinity complex anchor that binds to circulating albumin. That anchor is the whole difference between this molecule and the DAC-free version: instead of a pulse that clears in under an hour, the peptide is released slowly from its carrier and keeps growth hormone and IGF-1 elevated for days. No approved form exists, so the vial is sold and described as research material.
- 5 mg lyophilized powder per vial, single pack option
- Albumin-bound GHRH analogue, long-acting profile
- GMP-manufactured and HPLC-verified, COA per batch
- U.S. domestic and international shipping options
How CJC-1295 DAC Works
GHRH tells the pituitary to release its own growth hormone, and the analogue does the same job with a longer presence in the body. The published trial work reported a half-life of 5.8 to 8.1 days, with a single dose lifting plasma growth hormone two to ten times above baseline for six days and longer, and IGF-1 rising 1.5 to 3 fold while peaking over nine to eleven days at repeated doses of 30 to 60 mcg/kg. The DAC-free CJC-1295 no DAC blend behaves completely differently and is treated in a separate card.
Reconstitution & Research Use
Add bacteriostatic water down the vial wall and swirl, do not shake. Five milligrams with 2 ml gives 2.5 mg/ml, so 0.1 ml holds 250 mcg and reads as 10 units on a U-100 insulin syringe; the same 5 mg in 1 ml doubles the strength and 10 units become 500 mcg. Community material describes one or two injections a week to follow the long half-life, a schedule that pairs naturally with a short ghrelin-receptor peptide such as Ipamorelin or GHRP-2, taken on an empty stomach. Reported side effects in the class are fluid retention, joint and muscle pain, injection-site reactions and shifts in glucose tolerance, all of which call for bloodwork rather than guesswork.
Quality & Authenticity
Each batch is produced under GMP conditions and checked by HPLC, with a Certificate of Analysis held for the batch. Keep the sealed powder at 2-8 C away from light, and the mixed solution refrigerated.
For laboratory research only. Consult a healthcare professional before use.
Specifications
| Brand | Dragon Pharma |
| Active Substance | CJC-1295 with DAC |
| Dosage | 5 mg per vial |
| Package | 1 lyophilized vial |
| Form | Freeze-dried powder, requires reconstitution |
| Drug Class | Research peptide, GHRH analogue |
| Manufacturing | GMP-certified |
| Testing | HPLC per batch, COA on file |
| Shipping | U.S. domestic and international |
Stacks
FAQ
Before you ask
Questions, answered
DAC stands for drug affinity complex, an anchor that lets the peptide bind circulating albumin. That binding is what stretches the half-life from roughly half an hour to between 5.8 and 8.1 days, turning a short pulse of growth hormone into a sustained level of growth hormone and IGF-1.
Once or twice a week appears in vendor and community material, and that spacing follows from the half-life rather than from a trial protocol. No single research arrangement is standard, and the sources checked for this card contain no female schedule and no approved dose.
The GHRH sequence is related, but the anchor changes the behavior completely. Without DAC the peptide is cleared in roughly thirty minutes and injected daily to produce a pulse; with DAC it holds growth hormone and IGF-1 up for days and is injected about once or twice a week. The two are sold as separate packs and cannot be described with the same numbers.
One injection lifted plasma growth hormone 2 to 10 times above baseline for six days and more, and IGF-1 rose 1.5 to 3 fold, peaking over 9 to 11 days and staying high for up to 28 days when dosing was repeated at 30 to 60 mcg/kg. Development for lipodystrophy stopped at phase II in 2006 after a participant death. Class side effects reported for GH secretagogues are fluid retention, joint and muscle pain, injection-site reactions and reduced glucose tolerance, so bloodwork is part of the picture.
Water goes down the glass wall and the vial is swirled, never shaken. Mixing 2 ml into the 5 mg vial leaves 2.5 mg per millilitre and a tenth of a millilitre holds 250 micrograms; 1 ml instead of 2 doubles that to 500 micrograms in the same 10 units. The single 5 mg option is listed on this page with U.S. domestic and international shipping, and price and stock appear against the option selector above.
No reviews yet
Be the first to share your experience with Dragon Pharma CJC-1295 DAC 5 mg Long-Acting GHRH Research Vial
Log in to write a reviewComplete the cycle
